Literature DB >> 24038025

Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Saskia A M van de Schans1, Liza N van Steenbergen, Jan Willem W Coebergh, Maryska L G Janssen-Heijnen, Dick Johan van Spronsen.   

Abstract

Survival rates determined at diagnosis are often too negative for cancer survivors. Conditional relative survival reflects actual prognosis during follow-up better. Data from all 54,015 patients newly diagnosed in the Netherlands with B-cell non-Hodgkin lymphoma during 1989-2008, aged 15-89 years (Netherlands Cancer Registry), were used. Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diagnosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for survivors of indolent B-cell non-Hodgkin lymphoma improved slightly with each additional year survived up to 91%. For patients with aggressive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and gradually thereafter to 93% after 16 years. There were differences between morphological entities. Initial differences in conditional relative survival at diagnosis between groups with different disease stages became smaller with increasing number of years survived. Age remained a prognostic indicator, also after prolonged follow-up. These results help caregivers to plan optimal surveillance and inform patients about their actual prognosis during follow-up. Long-lasting excess mortality among patients with B-cell non-Hodgkin lymphoma indicates the need for additional care long after their diagnosis.

Entities:  

Mesh:

Year:  2013        PMID: 24038025      PMCID: PMC3912965          DOI: 10.3324/haematol.2012.081885

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

1.  Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases.

Authors:  Hermann Brenner; Bernard Rachet
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

2.  Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry.

Authors:  D J van Spronsen; M L G Janssen-Heijnen; V E P P Lemmens; W G Peters; J W W Coebergh
Journal:  Eur J Cancer       Date:  2005-05       Impact factor: 9.162

3.  An alternative approach to monitoring cancer patient survival.

Authors:  H Brenner; O Gefeller
Journal:  Cancer       Date:  1996-11-01       Impact factor: 6.860

4.  Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1977-09

5.  Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.

Authors:  Saskia A M van de Schans; Maryska L G Janssen-Heijnen; Marten R Nijziel; Ewout W Steyerberg; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

6.  Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996.

Authors:  D J van Spronsen; M L Janssen-Heijnen; W P Breed; J W Coebergh
Journal:  Ann Hematol       Date:  1999-07       Impact factor: 3.673

7.  A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index.

Authors:  Maryska L G Janssen-Heijnen; Dick Johan van Spronsen; Valery E P P Lemmens; Saskia Houterman; Kees D G W Verheij; Jan Willem W Coebergh
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

8.  Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark.

Authors:  Halla Skuladottir; Jorgen H Olsen
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

9.  Risk of leukemia following treatment for non-Hodgkin's lymphoma.

Authors:  L B Travis; R E Curtis; M Stovall; E J Holowaty; F E van Leeuwen; B Glimelius; C F Lynch; A Hagenbeek; C Y Li; P M Banks
Journal:  J Natl Cancer Inst       Date:  1994-10-05       Impact factor: 13.506

10.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

View more
  6 in total

1.  Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.

Authors:  Eric M Ammann; Tait D Shanafelt; Kara B Wright; Bradley D McDowell; Brian K Link; Elizabeth A Chrischilles
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Authors:  Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund
Journal:  Cancer       Date:  2018-12-11       Impact factor: 6.860

Review 3.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors:  Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

4.  Epidemiology of Marginal Zone Lymphoma.

Authors:  James R Cerhan; Thomas M Habermann
Journal:  Ann Lymphoma       Date:  2021-03-30

5.  Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands.

Authors:  Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Eduardus F M Posthuma; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  Blood Cancer J       Date:  2021-01-13       Impact factor: 11.037

Review 6.  How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Authors:  Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe
Journal:  J Hematol Oncol       Date:  2021-01-06       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.